The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s liver cancer diagnostics market report forecasts the liver cancer diagnostics market size to grow to $12.14 Billion by 2027, with a CAGR (compound annual growth rate) of more than 7%.

Learn More On The Liver Cancer Diagnostics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Liver Cancer Diagnostics Market Size Forecast
The global liver cancer diagnostics market is expected to grow from $8.46 billion in 2022 to $9.19 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global liver cancer diagnostics market size is expected to reach $12.14 billion in 2027 at a CAGR of 7.2%.

North America held the largest liver cancer diagnostics market share.

Key Liver Cancer Diagnostics Market Driver ­– Rise In The Prevalence Of Liver Cancer
For example, according to the American Cancer Society’s Cancer Facts & Figures 2023 report, published in January 2023, the number of new cases of liver and intrahepatic bile duct cancer in females in the United States reached 13,230 in 2023, up from 12,640 in 2020. Furthermore, an anticipated 41,210 new instances of liver cancer will be detected in the United States in 2023, with 29,380 people dying. As a result, the increased occurrence of liver cancer is propelling the liver cancer diagnostic market forward.

Request for A Sample Of The Global Liver Cancer Diagnostics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10481&type=smp

Key Liver Cancer Diagnostics Market Trend – Technological Advancement
To maintain their market position, major businesses in the liver cancer diagnostics market are focused on the development of breakthrough diagnostic technologies. For example, in December 2021, Helio Health, a pharmaceutical consultant located in the United States, and Fulgent Genetics Inc., a cancer therapies company based in the United States, launched HelioLiver, a new liquid biopsy test for the early identification of liver cancer. It is a multi-analyte blood test that integrates serum protein markers and cell-free DNA (cfDNA) methylation patterns to detect hepatocellular carcinoma (HCC), the most common kind of liver cancer. When compared to when cancer has metastasized, HelioLiver has the potential to provide more curative treatment options, which have been shown to boost five-year survival rates by up to 13 times.

Liver Cancer Diagnostics Market Segment
1) By Type: Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Other Types
2) By Screening: Laboratory Testing, Imaging, Endoscopy, Biopsy, Other Screenings
3) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
4) By End Use: Hospitals And Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And CRO Laboratories

Liver Cancer Diagnostics Market Major Players and Strategies
Major players in the liver cancer diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V, Thermo Fisher Scientific Inc., Siemens Healthineers, Becton Dickinson & Company, Illumina Inc., Koninklijke Philips N.V., Epigenomics AG, C.R. Bard Inc., Hologic Inc., Digna Biotech SL, Biocept Inc., Danaher Corporation, and Foundation Medicine Inc.

Fujifilm Holdings Corporation, a Japan-based corporation involved in healthcare and biotech product development, acquired Inspirata for an undisclosed sum in December 2022. Fujifilm will acquire Dynamyx digital pathology technology, and Inspirata workers and clients will join Fujifilm. The addition of digital pathology would enhance Fujifilm’s powerful Synapse® Enterprise Imaging portfolio, allowing pathology data and images to be integrated into a company’s electronic medical record system and assisting in the streamlining of treatment for cancer patients and care teams. Inspirata is a company established in the United States that provides oncology informatics and healthcare IT solutions.

The Liver Cancer Diagnostics Global Market Report 2023 covers regional data on liver cancer diagnostics market size, liver cancer diagnostics market trends and drivers, opportunities, strategies, and liver cancer diagnostics market competitor analysis. The countries covered in the liver cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The numerous procedures used to identify and diagnose liver cancer, a kind of cancer that starts in the liver, are referred to as liver cancer diagnostics. It is used to identify and diagnose liver cancer early using imaging and molecular testing.

View More Reports Related To The Liver Cancer Diagnostics Market –
Cancer Biologics Global Market Report 2023
Cancer Diagnostics Global Market Report 2023
Liver Diseases Therapeutics Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: